MedicalCV Establishes Scientific Advisory Board Comprised of Distinguished Cardiac Surgeons and Scientific Experts
13 Julho 2005 - 11:15AM
PR Newswire (US)
MedicalCV Establishes Scientific Advisory Board Comprised of
Distinguished Cardiac Surgeons and Scientific Experts Dr. Patrick
M. McCarthy, Chief of Cardiothoracic Surgery at Northwestern
Memorial Hospital, Joins as Chairman of the Scientific Advisory
Board MINNEAPOLIS, July 13 /PRNewswire-FirstCall/ -- MedicalCV,
Inc. (OTC:MDCV) (BULLETIN BOARD: MDCV) , http://www.medcvinc.com/ ,
a cardiovascular surgery device manufacturer which utilizes a
laser-based technology for cardiac tissue ablation and focuses on
the surgical needs surrounding atrial fibrillation, announced today
that it has established its Scientific Advisory Board of prominent
cardiothoracic surgeons. MedicalCV is pleased to announce that
Patrick M. McCarthy, MD, Chief of Cardiothoracic Surgery and
Co-Director of the Bluhm Cardiovascular Institute at Northwestern
Memorial Hospital in Chicago, IL, and one of the world's
pre-eminent heart surgeons, will serve as Chairman of the
Scientific Advisory Board. In addition, twelve other prominent
cardiothoracic surgeons with extensive experience and expertise in
the treatment of atrial fibrillation have accepted positions on the
Scientific Advisory Board. This international and well-versed group
of advisors will provide management with pivotal scientific
guidance and will assist in establishing MedicalCV's current and
future research and development activities. The Scientific Advisory
Board will also provide clinical direction to support the
acceleration of MedicalCV's clinical procedures and marketing
efforts. These advisors bring impressive credentials in the cardiac
field that support and validate MedicalCV's strategic focus.
Combined, this group of advisors has well over one hundred years of
experience in the cardiovascular / heart space and patient care.
Chairman of the Scientific Advisory Board: -- Patrick M. McCarthy,
MD Chief of Cardiothoracic Surgery and Co-Director of the Bluhm
Cardiovascular Institute at Northwestern Memorial Hospital in
Chicago, IL Members of the Scientific Advisory Board: -- Baron L.
Hamman, MD Cardiothoracic Surgeon at Heart Place at Baylor
University Medical Center in Dallas, TX -- Michael P. Caskey, MD
Cardiothoracic Surgeon at Southwest Heart & Lung in Phoenix, AZ
-- Marc Gerdisch, M.D. Cardiothoracic Surgeon at Cardiac Surgery
Associates in Winfield, IL -- Lishan Aklog, MD Cardiothoracic
Surgeon at Mount Sinai Medical Center in New York, NY -- Sudhir
Srivastava, MD Cardiothoracic Surgeon at Cardiac Surgical
Associates of West Texas in Odessa, TX -- Carmelo Otero, MD
Cardiothoracic Surgeon at Cirujanos de Corazon Associates at
Baptist Medical Center in San Antonio, TX -- Lonnie Whiddon, MD
Cardiothoracic Surgeon at Texas Cardiothoracic Surgery Associates
in Dallas, TX -- J. Michael Smith, MD Cardiothoracic Surgeon at
Good Samaritan Hospital in Cincinnati, OH -- Robert R. Lazzara, MD
Cardiothoracic Surgeon at Cardiac Surgical Associates in Tampa, FL
-- Yousuf Mahomed, MD Cardiothoracic Surgeon at Indiana University
School of Medicine, Clarian Cardiovascular Center in Indianapolis,
IN -- Rainer G. Moosdorf, MD Professor and Director, Cardiac and
Thoracic, Vessel Surgery at Phillips University of Marburg Hospital
in Marburg, Germany -- Robert Svenson, MD Director of
Electrophysiology, Central New York Cardiology in Utica, NY
Commenting on the new Scientific Advisory Board, Marc P. Flores,
President and Chief Executive Officer of MedicalCV, said, "We are
very pleased to have such a distinguished group of surgeons with a
wealth of experience, outstanding achievements and vast industry
relationships, join our Scientific Advisory Board to help guide the
research and development efforts of MedicalCV. End user input is
essential at this point of development. All of these high caliber
individuals are proficient in various treatments for atrial
fibrillation, and are familiar with all of the technologies and
energy sources available on the market today. We believe this
board's input and experience will assist us in creating the
stand-alone, minimally invasive (closed chest, beating heart)
treatment for atrial fibrillation which is being designed with our
laser platform of technology to mirror the positive outcomes
associated with the gold standard Cox-Maze surgical procedure." He
continued, "These advisors are all very active in the cardiac
field, and are all well-regarded physicians. This renowned advisory
board is validation to our products, concepts and the highly
focused efforts of MedicalCV's management team. All of these
physicians have a strong interest in the treatment of atrial
fibrillation, which is a market that is projected to grow to $1.5
billion worldwide by 2008," Mr. Flores concluded. Dr. Patrick M.
McCarthy, Chairman of MedicalCV's Scientific Advisory Board, said,
"It is an honor to be a part of something as exciting as what
MedicalCV is working on. The disease of atrial fibrillation is
significant and prevalent worldwide. MedicalCV's laser-based
technology offers momentous promise for the future treatment of
atrial fibrillation in an elegant and minimally invasive fashion.
The advisory board will be working closely with the management team
to advance the ATRILAZE(TM) system's research and development,
acceptance and utilization by cardiac surgeons into their practice,
as an ideal and preferred treatment option for patients with atrial
fibrillation." About MedicalCV, Inc. MedicalCV, Inc., a
cardiovascular surgery device manufacturer, focuses on the
development and introduction of products designed to improve
patient outcomes through the early treatment of cardiovascular
disorders and disease specifically, products used by cardiac
surgeons to ablate cardiac tissue as a potential means to treat
atrial fibrillation. The Company's core technology is the
ATRILAZE(TM) Surgical Ablation System for use in cardiac tissue
ablation procedures in open-heart surgery. The Company acquired
this technology in August 2003 and received its FDA 510(k)
clearance in November 2004. The ATRILAZE(TM) system is now
available commercially for concomitant open-heart surgical
procedures. The Company's common stock is traded on the OTC
Bulletin Board under the symbol "MDCV." For further information on
MedicalCV, Inc., please visit http://www.medcvinc.com/ . You may
register to receive MedicalCV's future press releases and to be
added to the Company's distribution list by visiting:
http://www.roiny.com/form.php . This release contains certain
forward-looking statements of expected future developments, as
defined in the Private Securities Litigation Reform Act of 1995.
The forward-looking statements in this release refer to our
expectations regarding our development of products for the
minimally invasive treatment of atrial fibrillation, and the
potential size of markets for such products. These forward-looking
statements reflect management's expectations and are based on
currently available data; however, actual results are subject to
future risks and uncertainties, which could materially affect
actual performance. Risks and uncertainties that could affect such
performance include, but are not limited to, the following: the
Company's ability to fund significant capital needs; market
acceptance in the U.S. of the Company's cardiovascular products;
acceptance of minimally invasive techniques for the reduction of
atrial fibrillation through ablation; potential reductions in
pricing by competitors; the costs of licensing and acquiring new
products and technologies; the time and costs involved in obtaining
regulatory clearance for cardiovascular products; competing
technological and market developments; physician acceptance of the
Company's cardiovascular products; dependence upon governmental
reimbursements and third party supplies; and the strength of the
market for cardiovascular products. For more detailed information
about these risks and uncertainties, please review the Company's
current report on Form 8-K filed with the Securities and Exchange
Commission on May 17, 2005. These events and uncertainties are
difficult or impossible to predict accurately and many are beyond
the Company's control. The Company assumes no obligation to
publicly release the results of any revisions that may be made to
any forward-looking statements to reflect events or uncertainties
after the date of such statements or to reflect the occurrence of
anticipated or unanticipated events. The Company cites estimates of
third parties as to the potential size of markets for its products;
however, there can be no assurance such estimates will prove
accurate. MedicalCV, Inc. Contact: Investor Relations Contact: John
H. Jungbauer ROI Group Associates Vice President, Finance & CFO
Robert Giordano Phone 651.452.3000 President Phone 212.495.0200,
ext. 10 http://www.medcvinc.com/ DATASOURCE: MedicalCV, Inc.
CONTACT: John H. Jungbauer, Vice President, Finance & CFO of
MedicalCV, Inc., +1-651-452-3000, or ; or Investor Relations,
Robert Giordano, President of ROI Group Associates,
+1-212-495-0200, ext. 10, or Web site: http://www.medcvinc.com/
http://www.roiny.com/form.php
Copyright